David Laharie

39PUBLICATIONS
62CO-AUTHORS
Medical infection agents (incl. prions)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|May 09, 2026
Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis.

|May 01, 2026
The GETAID: over 40 years of academic research in IBD.

|Apr 27, 2026
One-Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real-World GETAID Study.

|Apr 20, 2026
Patterns of conventional therapy use and advanced therapy initiation drivers in inflammatory bowel disease.

|Mar 25, 2026
Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID.

Louis Calméjane, Catherine Reenaers, Claire Gay

|Sep 11, 2025
Editorial: Ulcerative Colitis Management in the Biologic Era-Data From the English Healthcare Databases.

Guillaume Le Cosquer, David Laharie

Pageof 7

Frequent Collaborators

13 joint publications

Laurent Peyrin-Biroulet

12 joint publications

Guillaume Bouguen

11 joint publications

Aurelien Amiot

9 joint publications

Mathurin Fumery